Abstract:BackgroundRelease and insufficient removal of endogenous nucleic acids may be involved in triggering autoimmune reactions important in the initiation of systemic autoimmune diseases including rheumatoid arthritis (RA). Nucleic acid sensing molecules, such as the endosomal Toll-like receptors (TLRs) 7 and 9, have been linked to pathogenic autoimmune processes, but their role in RA is less clear. Data obtained in rats with pristane-induced arthritis (PIA) suggested involvement of TLR9 in the pathogenesis of this arthritis model1.ObjectivesTo gain more insight into the role of TLR9 in autoimmune arthritis, TLR9 inhibition with specific oligodeoxynucleotide sequences (ODN)2 was investigated in rats with PIA. To further investigate TLR9 involvement, streptococcal cell wall (SCW) arthritis was induced in TLR9-/- mice.MethodsArthritis was induced in mice with SCW lysates and in rats with the mineral oil pristane. Rats were treated with a TLR9 antagonist, starting before disease induction. Arthritis was scored using established scoring systems, inflammation and bone erosion were quantified by histological analysis. Levels of α−1-acid-glycoprotein (AGP), rheumatoid factor (RF) and IL-6 in sera were analysed. The role of TLR9 in osteoclast differentiation and activation was investigated in vitro.ResultsIn PIA, the TLR9 antagonist reduced arthritis severity by ~50%, which was accompanied by a reduction of AGP, IL-6 and RF. TLR9 inhibition led to reduced inflammation, bone erosion and cartilage degradation. Moreover, the T cell-dependent chronic phase of SCW arthritis was significantly suppressed in TLR9-/- mice. Remarkably, TLR7 and TLR9 mRNA levels strongly differed in the course of in vitro osteoclastogenesis. Whereas TLR7 expression did not change throughout osteoclastogenesis, expression of TLR9 was higher in precursor cells than in mature osteoclasts and stimulation with a TLR9 agonist (CpG) completely inhibited osteoclastogenesis.ConclusionsTaken together, the results suggest a role for TLR9 in the T cell-dependent phases of PIA and SCW arthritis thus an important involvement of the DNA (CpG) recognising TLR9 in the initiation of autoimmune arthritis and during osteoclastogenesis. The precise role(s) of TLR9 in the different stages of arthritis needs to be further elucidated in future experiments.References[1] Hoffmann MH, et al. Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis. J Autoimmun, 2011;36(3–4):288–300. [2] Duramad O, et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol, 2005;174(9):5193–200.Disclosure of InterestNone declared

Molecular cloning and characterization of a novel anti-TLR9 intrabody

Computational Discovery and Experimental Confirmation of TLR9 Receptor Antagonist Leads

Murine TLR2 expression analysis and systemic antagonism by usage of specific monoclonal antibodies.

TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity

TLR10 (CD290) Is a Regulator of Immune Responses in Human Plasmacytoid Dendritic Cells

A Novel Antagonist of TLR9 Blocking All Classes of Immunostimulatory CpG-ODNs

AB0040 Toll-like receptor 9 influences inflammatory arthritis and osteoclastogenesis

Discovery of Novel Small Molecule Dual Inhibitor Targeting Toll-Like Receptors 7 and 9

Cell-free synthesis of human toll-like receptor 9 (TLR9): Optimization of synthesis conditions and functional analysis

Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

A Tumor Necrosis Factor (TNF) Receptor-Igg Heavy Chain Chimeric Protein As a Bivalent Antagonist of TNF Activity.

TLR10 Is a Negative Regulator of Both MyD88-Dependent and -Independent TLR Signaling

Toll‐like Receptor 9 constitutively traffics from the ER to the lysosome prior to stimulation with CpG DNA

TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.

Novel Small Molecule Inhibitors of TLR7 and TLR9: Mechanism of Action and Efficacy In Vivo

Select Targeting of Intracellular Toll-interleukin-1 Receptor Resistance Domains for Protection Against Influenza-Induced Disease.

TLR9 Monotherapy in Immune-Competent Mice Suppresses Orthotopic Prostate Tumor Development

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

TLR9 Regulates Host Defense Via Modulation of Peritoneal B1 Cell Recruitment and Functions During Intra-Abdominal Sepsis

TLR9 Promotes Tolerance by Restricting Survival of Anergic Anti-DNA B Cells, Yet Is Also Required for Their Activation

The N‐terminal Box 1 Tyrosine in the TIR Domain of TLR9 is Critical for Endoplasmic Reticulum Egress and Maturation of the Receptor